Some Immunomodulators Tied to Lower COVID Pneumonia Deaths

TOPLINE Cytokine inhibitors lowered 30-day mortality in adults hospitalized with COVID community-acquired pneumonia (CAP) , and corticosteroids and JAK inhibitors probably did so, according to a systematic review and meta-analysis of 196 studies. No immunomodulatory therapy showed a consistent mortality benefit in non-COVID or mixed-cause CAP at 30 or 90 days, and none showed a clear benefit at 90 days in COVID CAP. METHODOLOGY Researchers conducted a systematic review and meta-analysis of 196 studies (123 randomized controlled trials [RCTs] and 73 nonrandomized studies of interventions) comprising 89,117 adults hospitalized with CAP. Eligible studies evaluated any immunomodulatory therapy started for CAP, compared with standard of care or with another therapy. Outcomes were all-cause mortality at 28/30 days and at 90 days. Treatments were classified by mechanism of action and analyzed in pairwise random-effects meta-analyses. COVID and non-COVID or mixed-cause CAP were analyzed separately. Evidence from RCTs was prioritized, and primary analyses were limited to comparisons with at least five studies. TAKEAWAY In COVID CAP, cytokine inhibitors were associated with reduced 30-day mortality (odds ratio [OR], 0.84; 95% CI, 0.76-0.93; high certainty), as were JAK inhibitors (OR, 0.66; 95% CI, 0.47-0.93; moderate certainty) and corticosteroids (OR, 0.87; 95% CI, 0.77-1.00; moderate certainty). Among cytokine inhibitors, interleukin (IL)-6 inhibitors reduced 30-day mortality (OR, 0.87; 95% CI, 0.78-0.97), whereas IL-1 inhibitors showed a possible but uncertain benefit (OR, 0.65; 95% CI, 0.39-1.10). For 90-day mortality in COVID CAP, only cytokine inhibitors were studied in at least five trials, and the result was not statistically significant (OR, 0.68; 95% CI, 0.45-1.03; low certainty). Among patients admitted to the ICU with COVID, cytokine inhibitors showed no statistically significant reduction in mortality. In non-COVID or mixed-cause CAP, corticosteroids may have reduced 30-day mortality, but the result was not statistically significant (OR, 0.76; 95% CI, 0.56-1.01; low certainty), and the evidence for 90-day mortality was very uncertain. Other categories, including convalescent plasma, complement inhibitors, and granulocyte colony-stimulating factor/granulocyte-macrophage colony-stimulating factor, showed no clear benefit. IN PRACTICE "Given that mortality in severe CAP remains high, these findings emphasize the importance of understanding dysregulated host inflammation and the impact of immunomodulatory strategies on clinical outcomes," the authors of the study wrote. SOURCE The study was led by Luke Flower, Victor Phillip Dahdaleh Heart & Lung Research Institute, University of Cambridge in Cambridge, England. It was published online on November 6, 2026, in Clinical Microbiology and Infection . LIMITATIONS Most identified studies addressed COVID, which left little evidence for other CAP etiologies. Heterogeneity persisted across studies, and ICU admission was an imperfect proxy for disease severity given the global variation in ICU access. Additionally, confounder adjustment varied across nonrandomized studies, and only mortality was assessed. DISCLOSURES Funding came from the University of Cambridge, the National Institute for Health and Care Research, UK Research and Innovation Medical Research Council, and others. Some authors reported receiving fellowships, royalties, and consulting fees and having other ties with various sources. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.